Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab

BACKGROUND: The landmark study of durvalumab as consolidation therapy in NSCLC patients (PACIFIC trial) demonstrated significantly longer progression-free survival (PFS) in patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) treated with durvalumab (immunotherapy, IO) the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jazieh, Khalid, Khorrami, Mohammadhadi, Saad, Anas, Gad, Mohamed, Gupta, Amit, Patil, Pradnya, Viswanathan, Vidya Sankar, Rajiah, Prabhakar, Nock, Charles J, Gilkey, Michael, Fu, Pingfu, Pennell, Nathan A, Madabhushi, Anant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905876/
https://www.ncbi.nlm.nih.gov/pubmed/35256515
http://dx.doi.org/10.1136/jitc-2021-003778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905876/
https://www.ncbi.nlm.nih.gov/pubmed/35256515
http://dx.doi.org/10.1136/jitc-2021-003778

Ejemplares similares